Financial Performance - Revenue increased by 18% for the three months ended December 31, 2021, compared to the same period in 2020, driven by both Life Sciences Products and Life Sciences Services segments [166]. - Revenue increased by 18% to $139.652 million for the three months ended December 31, 2021, compared to $118.142 million for the same period in 2020 [174]. - The Life Sciences Products segment revenue increased by 10% to $49.877 million, while the Life Sciences Services segment revenue increased by 24% to $89.775 million [179]. - Income from continuing operations increased to $2.858 million, while income from discontinued operations rose significantly to $40.462 million [173]. - Revenue from discontinued operations was $203.7 million for the three months ended December 31, 2021, compared to $131.4 million in 2020 [199]. - Net income from discontinued operations increased to $40.5 million for the three months ended December 31, 2021, up from $23.3 million in 2020 [199]. Gross Margin and Operating Expenses - Gross margin was 48.0% for the three months ended December 31, 2021, slightly down from 48.5% in the prior year [166]. - Gross profit was $67.044 million, resulting in a gross margin of 48.0%, down from 48.5% in the prior year [174]. - Operating expenses rose by $10.4 million compared to the three months ended December 31, 2020, due to increases in research and development and selling, general, and administrative expenses [166]. - Operating expenses rose by $10.4 million to $67.369 million, driven by increases in research and development and selling, general, and administrative expenses [174]. - Research and development expenses totaled $6.485 million, an increase of 28% compared to $5.084 million in the prior year [188]. - Selling, general, and administrative expenses increased by 17% to $60.711 million, up from $51.930 million in the previous year [190]. Operating Loss - The company reported an operating loss of $0.3 million for the three months ended December 31, 2021, compared to an operating income of $0.4 million in the prior year [166]. - The company reported an operating loss of $0.325 million, compared to an operating income of $0.356 million in the same period last year [180]. Cash and Cash Equivalents - Cash and cash equivalents totaled $273.0 million as of December 31, 2021, down from $285.3 million as of September 30, 2021, reflecting a decrease of $12.3 million [167]. - Cash and cash equivalents, restricted cash, and marketable securities totaled $231.8 million as of December 31, 2021, down from $244.0 million as of September 30, 2021 [201]. - Cash flows from operating activities were $15.6 million for the three months ended December 31, 2021, compared to $43.7 million in the same period of 2020 [204][205]. - Cash used in investing activities was $18.4 million during the three months ended December 31, 2021, primarily for capital expenditures [206]. Strategic Initiatives - The company completed the sale of its semiconductor automation business for $3.0 billion in cash on February 1, 2022, marking a strategic shift to focus on life sciences [154]. - The company plans to continue investing in research and development and making strategic acquisitions to expand its offerings in the life sciences market [163]. Global Presence - The life sciences business employs approximately 2,900 personnel and operates in over 90 countries, indicating a strong global presence [159][160]. Foreign Currency and Interest Rates - Sales in currencies other than the U.S. dollar accounted for approximately 38% of total sales during the three months ended December 31, 2021 [223]. - Liquid assets denominated in non-functional currencies were approximately $110.0 million at December 31, 2021 [224]. - Foreign currency losses incurred during the three months ended December 31, 2021, were $1.9 million, compared to $0.8 million in the same period of 2020 [224]. - A hypothetical 10% change in foreign exchange rates would result in an approximate change of $3.1 million in net income for the three months ended December 31, 2021 [224]. - A hypothetical 100 basis point change in interest rates would result in a $0.1 million change in interest expense incurred during the three months ended December 31, 2021 [220]. - The company utilizes forward contracts to mitigate exposures to currency movement [224]. Interest Expense - Interest expense decreased to $0.5 million for the three months ended December 31, 2021, compared to $0.6 million in the same period of 2020 [195]. - During the three months ended December 31, 2021, cash interest expense incurred on outstanding term loans was $0.3 million [220].

PART I [Item 1. Business](index=4&type=section&id=Item%201.%20Business) Brooks Automation, a global life science sample management provider, is rebranding as Azenta Life Sciences following the planned $3.0 billion sale of its semiconductor automation business - The company is a leading global provider of life science sample exploration and management solutions, serving pharmaceutical, biotechnology, and research institutions[7](index=7&type=chunk) - In Q4 of fiscal year 2021, the company agreed to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (THL) for approximately **$3.0 billion** in cash, now treated as discontinued operations[10](index=10&type=chunk) - The remaining life sciences business, comprising Life Sciences Products and Life Sciences Services segments, will be rebranded as Azenta Life Sciences in the first half of fiscal year 2022[10](index=10&type=chunk) - The business is organized into two reportable segments: Life Sciences Products (automated ultra-cold storage, consumables, instruments) and Life Sciences Services (genomic analysis, sample repository solutions, informatics)[14](index=14&type=chunk)[15](index=15&type=chunk)[19](index=19&type=chunk) - As of September 30, 2021, the company employed approximately **2,800 people** and utilized **80 contingent associates**, with approximately **48% of employees being gender diverse** and **41% of U.S.-based employees identifying as racially diverse**[34](index=34&type=chunk)[35](index=35&type=chunk) [Item 1A. Risk Factors](index=16&type=section&id=Item%201A.%20Risk%20Factors) The company faces risks from the COVID-19 pandemic, the pending semiconductor business sale, operational fluctuations, international complexities, and reliance on key suppliers and customers - The COVID-19 pandemic could adversely affect financial conditions through supply chain disruptions, logistics issues, and reduced customer demand[43](index=43&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk) - The pending sale of the semiconductor automation business poses risks, including potential disruption, management distraction, and negative impacts on stock price and business prospects if the sale is not completed[50](index=50&type=chunk)[52](index=52&type=chunk) - Operating results are subject to significant fluctuation due to factors like order timing, product mix, new product acceptance, and competitive pressures[53](index=53&type=chunk) - International operations, which accounted for **38% of revenue in FY2021**, expose the company to risks such as tariffs, currency fluctuations, and political instability[57](index=57&type=chunk) - The company relies on a limited number of customers, with the **ten largest accounting for approximately 19% of total revenue in fiscal year 2021**[97](index=97&type=chunk) - The company's stock price is volatile, having fluctuated between a high of **$109.17** and a low of **$46.70 per share** from the beginning of fiscal year 2020 through the end of fiscal year 2021[101](index=101&type=chunk) [Item 1B. Unresolved Staff Comments](index=39&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments - None[109](index=109&type=chunk) [Item 2. Properties](index=39&type=section&id=Item%202.%20Properties) The company's primary facilities include an owned 298,000 sq. ft. headquarters in Chelmsford, MA, which is part of the planned semiconductor business sale, and leased sites in Indianapolis and Suzhou Principal Facilities as of September 30, 2021 | Location | Functions | Square Footage (Approx.) | Ownership Status/Lease Expiration | | :--- | :--- | :--- | :--- | | Chelmsford, Massachusetts | Corporate headquarters, training, manufacturing, R&D and sales & support | 298,000 | Owned | | Indianapolis, Indiana | Sample storage, sales & support | 116,700 | September 2038 | | Suzhou, China | Laboratory & office | 116,800 | June 2022 | - The Chelmsford, MA facility will be included in the sale of the semiconductor automation business, after which the company will lease space there temporarily while transitioning to a new corporate headquarters[110](index=110&type=chunk) [Item 3. Legal Proceedings](index=39&type=section&id=Item%203.%20Legal%20Proceedings) The company is subject to various legal proceedings arising in the ordinary course of business but believes that none of these claims will have a material adverse effect on its consolidated financial condition or results of operations as of the report date - The company is subject to various legal proceedings from the ordinary course of business but does not expect any to have a material adverse effect on its financial condition or operations[112](index=112&type=chunk) [Item 4. Mine Safety Disclosures](index=39&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[113](index=113&type=chunk) PART II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=40&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's stock symbol will change to "AZTA" on December 1, 2021, with quarterly dividends ceasing post-semiconductor business sale, and no share repurchases in fiscal year 2021 - The company's stock trading symbol will change from "BRKS" to "**AZTA**" on **December 1, 2021**[114](index=114&type=chunk) - The company intends to discontinue its quarterly dividend upon the completion of the sale of its semiconductor automation business[116](index=116&type=chunk) Comparative 5-Year Cumulative Total Shareholder Return | | 9/30/2016 | 9/30/2017 | 9/30/2018 | 9/30/2019 | 9/30/2020 | 9/30/2021 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Brooks Automation, Inc. | $100.00 | $227.15 | $265.67 | $284.25 | $358.55 | $797.18 | | Nasdaq/NYSE American/NYSE | $100.00 | $120.08 | $136.91 | $139.19 | $159.63 | $199.90 | | Peer Group | $100.00 | $162.43 | $174.41 | $205.33 | $233.59 | $359.77 | - No shares were repurchased under the company's **$50.0 million** share repurchase program during the fiscal year ended September 30, 2021[121](index=121&type=chunk) [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=43&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section analyzes the financial condition and operating results of the continuing Life Sciences business, detailing revenue growth, margin expansion, and liquidity, while noting the planned semiconductor business sale and rebranding [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=76&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rate fluctuations on its variable-rate term loan and foreign currency exposure from non-U.S. dollar sales, partially mitigated by forward contracts - The company is exposed to interest rate risk on its variable-rate term loan; a hypothetical **100 basis point** change in interest rates would result in a **$0.5 million** change in annual interest expense[251](index=251&type=chunk) - Sales in currencies other than the U.S. dollar constituted **37% of total sales in fiscal year 2021**, and the company utilizes forward contracts to mitigate currency exposure[253](index=253&type=chunk)[254](index=254&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=77&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements for fiscal years 2019-2021, restated to reflect the semiconductor automation business as a discontinued operation [Item 9. Changes in and Disagreements with Accountants on Financial Accounting and Financial Disclosure](index=153&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Financial%20Accounting%20and%20Financial%20Disclosure) This item is not applicable to the company - Not applicable[534](index=534&type=chunk) [Item 9A. Controls and Procedures](index=153&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management and the independent auditor concluded that the company's disclosure controls and internal control over financial reporting were effective as of September 30, 2021 - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of September 30, 2021[535](index=535&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of September 30, 2021, based on the COSO framework[537](index=537&type=chunk) [Item 9B. Other Information](index=154&type=section&id=Item%209B.%20Other%20Information) There is no other information to report for this item - None[539](index=539&type=chunk) PART III [Item 10. Directors, Executive Officers and Corporate Governance](index=154&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) The information required for this item is incorporated by reference from the company's definitive proxy statement for its 2022 annual meeting of stockholders - Information is incorporated by reference from the registrant's Proxy Statement[540](index=540&type=chunk) [Item 11. Executive Compensation](index=154&type=section&id=Item%2011.%20Executive%20Compensation) The information required for this item is incorporated by reference from the company's definitive proxy statement for its 2022 annual meeting of stockholders - Information is incorporated by reference from the registrant's Proxy Statement[541](index=541&type=chunk) [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=154&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) The information required for this item is incorporated by reference from the company's definitive proxy statement for its 2022 annual meeting of stockholders - Information is incorporated by reference from the registrant's Proxy Statement[541](index=541&type=chunk) [Item 13. Certain Relationships and Related Transactions, and Director Independence](index=154&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The information required for this item is incorporated by reference from the company's definitive proxy statement for its 2022 annual meeting of stockholders - Information is incorporated by reference from the registrant's Proxy Statement[542](index=542&type=chunk) [Item 14. Principal Accountant Fees and Services](index=154&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) The information required for this item is incorporated by reference from the company's definitive proxy statement for its 2022 annual meeting of stockholders - Information is incorporated by reference from the registrant's Proxy Statement[543](index=543&type=chunk) PART IV [Item 15. Exhibits and Financial Statement Schedules](index=155&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists financial statements and comprehensive exhibits filed with the Form 10-K, including key agreements and compensation plans - The Consolidated Financial Statements are included under Part II, Item 8 of the Form 10-K[544](index=544&type=chunk) - Key exhibits filed include the Equity Interest Purchase Agreement for the sale of the semiconductor business, credit agreements, and various executive compensation and equity incentive plan documents[545](index=545&type=chunk)[546](index=546&type=chunk)[547](index=547&type=chunk) [Item 16. Form 10-K Summary](index=159&type=section&id=Item%2016.%20Form%2010-K%20Summary) No Form 10-K summary is provided - None[549](index=549&type=chunk)

Revenue and Growth - Revenue for the three months ended March 31, 2021 increased 30% to $286.6 million compared to the same period in the prior fiscal year[179] - Revenue for the six months ended March 31, 2021 increased 24% to $536.1 million compared to the same period in the prior fiscal year[180] - Revenue for the three months ended March 31, 2021, was $286.6 million, an increase of 30% compared to $220.2 million for the same period in the prior fiscal year[187] - Brooks Semiconductor Solutions Group segment reported revenue of $157.1 million for the three months ended March 31, 2021, a 26% increase from $124.9 million in the prior year[188] - Brooks Life Sciences Products segment revenue increased by 69% to $52.4 million for the three months ended March 31, 2021, compared to $31.0 million in the prior year[189] - Revenue generated outside the United States was $182.2 million, or 64% of total revenue, for the three months ended March 31, 2021, compared to 61% in the prior year[194] - The acquisitions of RURO and THB contributed $4.0 million in revenue for the six months ended March 31, 2021[193] Profitability and Margins - Gross margin for the three months ended March 31, 2021 was 44.4%, up from 41.0% in the corresponding period of the prior fiscal year, resulting in an increase in gross profit of $37.0 million[179] - Gross margin for the six months ended March 31, 2021 was 44.8%, up from 40.7% in the corresponding period of the prior fiscal year, resulting in an increase in gross profit of $65.1 million[180] - Operating income for the second quarter of fiscal year 2021 was $30.5 million, compared to $14.6 million for the same period in the prior fiscal year[179] - Operating income for the three months ended March 31, 2021, was $30.5 million, a 109% increase from $14.6 million in the same period of the prior fiscal year[195] - Brooks Semiconductor Solutions Group segment reported gross margins of 44.2% for the three months ended March 31, 2021, an increase of 5.3 percentage points from 38.9% in the prior fiscal year[208] - Brooks Life Sciences Products segment reported gross margins of 45.9% for the three months ended March 31, 2021, up 2.8 percentage points from 43.2% in the prior fiscal year[209] - Brooks Life Sciences Services segment reported gross margins of 43.8% for the three months ended March 31, 2021, a decrease of 0.2 percentage points from 44.0% in the prior fiscal year[210] Expenses and Financial Activities - Research and development expenses increased to $16.9 million for the three months ended March 31, 2021, compared to $15.3 million in the prior fiscal year[214] - Selling, general and administrative expenses rose to $79.7 million for the three months ended March 31, 2021, compared to $59.8 million in the prior fiscal year, driven by $19.9 million increase[218] - Interest expense decreased to $0.5 million for the three months ended March 31, 2021, down from $0.7 million in the prior fiscal year[225] - Cash used in investing activities was $42.4 million during the six months ended March 31, 2021, which included $25.5 million for capital expenditures and $15.1 million for an acquisition[241] - Cash outflows for financing activities totaled $13.3 million during the six months ended March 31, 2021, primarily due to cash dividend payments of $14.9 million[242] Cash and Liquidity - Cash, cash equivalents, restricted cash, and marketable securities were $334.3 million at March 31, 2021, an increase of $28.6 million from $305.7 million at September 30, 2020[181] - As of March 31, 2021, the company had cash and cash equivalents of $320.1 million, an increase from $295.6 million as of September 30, 2020, representing a growth of 8.5%[236] - Cash inflows from operating activities for the six months ended March 31, 2021, were $77.9 million, primarily driven by $86.5 million in earnings, including $49.8 million in net income[240] - The company had non-cancellable commitments of $266.4 million as of March 31, 2021, including $230.1 million for inventory purchases[254] Foreign Currency and Interest Rate Exposure - Approximately 40% of total sales during the six months ended March 31, 2021, were denominated in currencies other than the U.S. dollar, primarily by foreign subsidiaries[259] - A hypothetical 10% change in foreign exchange rates would result in an approximate change of $0.6 million and $3.8 million in net income for the six months ended March 31, 2021 and 2020, respectively[262] - Liquid assets denominated in non-functional currencies were approximately $92.8 million and $142.9 million at March 31, 2021 and September 30, 2020, respectively[260] - A hypothetical 100 basis point change in interest rates would result in a $0.3 million change in interest expense for the six months ended March 31, 2021[257] Corporate Developments and Future Outlook - The company invested more than 29% of its cumulative research and development spending in the life sciences market for the fiscal years ended 2020, 2019, and 2018[178] - The company launched the BioStore™ IIIv, which offers improved data management and sample security for vaccines and biologics stored at -80°C[178] - The company continues to focus on developing processes and technologies to streamline sample to data workflow in the life sciences sector[178] - The semiconductor solutions business continues to supply critical chip manufacturing equipment and support services globally, with no substantial negative impact from the COVID-19 pandemic on financial results[167] - The company expects to incur an additional $43 million to $47 million in capital expenditures related to the construction of a facility in Suzhou, China, over the next four years[243] Legal and Compliance - The company believes that none of the legal proceedings will have a material adverse effect on its consolidated financial condition or results of operations[266] - There were no changes in internal control over financial reporting that materially affected the company during the most recent fiscal quarter[264]

Table of Contents Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 Brooks Automation, Inc. (Exact name of Registrant as Specified in Its Charter) Delawa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 BROOKS AUTOMATION, INC. (Exact name of registrant as specified in its charter) Dela ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 BROOKS AUTOMATION, INC. (Exact name of registrant as specified in its charter) Del ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 BROOKS AUTOMATION, INC. (Exact name of registrant as specified in its charter) ...

Table of Contents Non-accelerated filer ☐ Smaller reporting company ☐ Commission File Number: 0-25434 Brooks Automation, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 04-3040660 (State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.) 15 Elizabeth Drive Chelmsford, Massachusetts (Address of Principal Executive Of ices) 01824 (Zip Code) 978-262-2400 (Registrant's telephone number, including area code) Securities registered pursuant to Section 1 ...